Regeneron, Sanofi asthma drug data fails to excite investors

    11 Sep by Tags:

    Regeneron, Sanofi asthma drug data fails to excite investors

    Shares of Regeneron Inc and Sanofi SA slid on Monday after late-stage trial data for their asthma drug, dupilumab, fell short of investor expectations. The drug, which is approved for atopic dermatitis, met its two main goals in patients with uncontrolled, persistent asthma. At 52 weeks, dupilumab reduced severe asthma attacks by 46 percent in the overall population in the late-stage trial.


    ...Read the rest of this story
    11 Sep by Tags:

    EU weighs strategy to compete in fintech with global rivals

    European Union finance ministers will discuss this week a plan to attract more financial-technology companies, in a bid to bridge the gap with global competitors and offset the loss of Europe's main fintech market after Britain leaves the bloc. The EU fintech market is dwarfed by those in China and the United States. It is concentrated in Britain, which is set to quit the EU in 2019, leaving the bloc with a fraction of the small but flourishing industry.


    ...Read the rest of this story
    11 Sep by Tags:

    Elliott squares off against KKR with Hitachi Kokusai stake

    TOKYO/HONG KONG (Reuters) - U.S. hedge fund Elliott Management Corp said on Monday it has a stake of just over 5 percent in Hitachi Kokusai Electric , putting pressure on a stalled takeover bid by U.S. buyout firm KKR & Co LP (KKR.N). Elliott's stake pits two Wall Street heavyweights against each other and underscores the increasing convergence of private equity investing and shareholder activism across the globe. KKR agreed in April to buy the chip-making equipment and video solutions business from Hitachi Ltd in a deal valuing the unit at about $2.3 billion.


    ...Read the rest of this story